Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
MedImmune LLC
With
AstraZeneca
In Escalation phase: MEDI4736 and gefitinib in NSCLC subjects In Expansion phase: Subjects with EGFR mutation positive locally advanced or metastatic NSCLC will be enrolled in expansion arms. Initiation of expansion arms with the recommended dose of MEDI4736 in combination with gefitinib will be based on an adequate safety and tolerability profile of the combination from the escalation phase.
Age
18–130
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. Provision of signed and dated, written informed consent
2. Male or female aged 18 years and older.
You may not be if
4. a.For Escalation Phase: At least one lesion (measurable and/or non-measurable) b.For Expansion Phase: At least one measurable lesion.
5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
* For Japan Escalation - the same as the global escalation I/E criteria except patients must be EGFR mutation positive
1. Any concurrent chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer treatment.
2. Any investigational agent, chemotherapy, immunotherapy, biologic, hormonal within 28 days of the first dose of study treatment
3. Inadequate bone marrow reserve or organ function
Clareo Health | MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC).
